- •This review provides a system-based practical approach for the safe implementation of targeted and immune therapies.
- •Creation of a multidisciplinary EDDIT team can provide shared experience and enhanced patient safety.
- •Education of providers, staff, trainees, and patients is a key function of the EDDIT team.
- •Immediate access to expert advice serves to avoid delays in recognition and management of adverse events.
Purchase one-time access:Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
One-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
- Immunotherapy in gynecologic cancers: Are we there yet?.Curr. Treat. Options in Oncol. 2017; 18: 59
- Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: American society of clinical oncology clinical practice guideline.J. Clin. Oncol. 2018; 36: 1714-1768
- Management of toxicities from immunotherapy: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.Ann. Oncol. 2017; 28: iv119-iv142
- Managing toxicities associated with immune checkpoint inhibitors: consensus recommendations from the Society for Immunotherapy of Cancer (SITC) Toxicity Management Working Group.J. Immunother. Cancer. 2017; 5: 95
- Adoptive T-cell therapy for cancer.Adv. Immunol. 2016; 130: 279-294
- Chimeric antigen receptor therapy.N. Engl. J. Med. 2018; 379: 64-73
- T-cell-based immunotherapy: adoptive cell transfer and checkpoint inhibition.Cancer Immunol. Res. 2015; 3: 1115-1122
- Chimeric antigen receptor- and TCR-modified T cells enter main street and wall street.J. Immunol. 2015; 195: 755-761
- Effect of lymphodepletion on donor T cells and the role of recipient cells persisting after cytotoxic treatments in cancer immunotherapies.Crit. Rev. Immunol. 2017; 37: 59-73
- Complete regression of metastatic cervical cancer after treatment with human papillomavirus-targeted tumor-infiltrating T cells.J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol. 2015; 33: 1543-1550
- Adoptive cell transfer using autologous tumor infiltrating lymphocytes in gynecologic malignancies.Gynecol. Oncol. 2018; 150: 361-369
- Chimeric antigen receptor T-cell therapy - assessment and management of toxicities.Nat. Rev. Clin. Oncol. 2018; 15: 47-62